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Ruth R. Shah and Adrian P. Bird*Editorial summary
Rett syndrome is a profound neurological disorder
caused by mutations in the MECP2 gene, but
preclinical research has indicated that it is potentially
treatable. Progress towards this goal depends on the
development of increasingly relevant model systems
and on our improving knowledge of MeCP2 function
in the brain.human and mouse (95% identical) and the parallel dy-Rett syndrome genetics
It is now 50 years since Andreas Rett reported his obser-
vations on 22 girls with similar clinical features, subse-
quently known as Rett syndrome (RTT). Classic RTT is
defined by a regression phase and subsequent
stabilization of diagnostic criteria, which include partial
or complete loss of spoken language, dyspraxic gait and
stereotypic hand movements such as ‘hand mouthing’
[1]. With very few familial cases available, it took a fur-
ther 33 years before mutations affecting a protein called
methyl-CpG-binding protein 2 (MeCP2) were shown to
be the almost exclusive cause of this neurological dis-
order. The MECP2 gene is located on the X chromo-
some, and RTT is classified as an X-linked dominant
disorder. Thus, as expected, males are more severely
affected and rarely survive infancy. Rett syndrome there-
fore overwhelmingly affects females, who, owing to X
chromosome inactivation, have a mixture of cells that
express either the wild-type or mutant version of
MeCP2. This cellular mosaicism defines RTT and high-
lights the importance of MeCP2 for proper neuronal
function. In the light of new insights into the function of
MeCP2 and the novel gene therapy technologies cur-
rently being developed, here we discuss recent progress
in understanding the molecular pathogenesis of this
complex disease and the search for a therapy.* Correspondence: a.bird@ed.ac.uk
Wellcome Trust Centre for Cell Biology, University of Edinburgh, Max Born
Crescent, Edinburgh EH16 5DS, UK
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeModel systems for studying Rett syndrome
Mouse models are a vital tool for studying RTT as
MeCP2 deficiency closely mimics the clinical features of
the human disorder, including motor defects and breath-
ing arrhythmia. Indeed, a recent study [2] of animals
expressing three Mecp2 mutations with differing average
clinical severity showed a matching severity spectrum in
the mice (Fig. 1) [3]. These findings reflect the high con-
servation of the MeCP2 amino acid sequence between
namics of MeCP2 expression during brain development.
Thus, despite differences in the brain structure and de-
velopmental timing between human and mouse, these
striking similarities suggest that the molecular conse-
quences of MeCP2 mutation are similar between the
two species. Early indications that RTT results exclu-
sively from absence of MeCP2 in the brain have recently
been reinforced by a mouse model that has normal
levels of central nervous system MeCP2, but lacks this
protein in the rest of the body, and shows none of the
major phenotypes associated with RTT-like mice [4].
Advances in cellular technologies have allowed further
development of human tissue-culture models of RTT [5, 6].
The ability to study a homogeneous population of
human neurons eliminates the complexity of the
brain, allows more precise genetic manipulation and
simplifies the interpretation of findings [5]. It also
streamlines screening of potential therapeutics and
viral delivery vectors in a human neuronal setting. In
addition to mice, a Mecp2-null rat model has been
produced (Sage Labs), and there has been progress
towards generating non-human primate models of
RTT [7] that should be beneficial for testing once
further phenotypic characterization is available.MeCP2—a genome-wide transcriptional repressor
Progress in understanding the molecular aetiology of
RTT has been facilitated by combining data from clinical
genetics and mouse models with cellular and biochem-
ical investigations. Importantly, nearly all RTT missensele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 Analysis of point mutations responsible for Rett syndrome (RTT) in human and mouse. a The primary protein structure of methyl-CpG-
binding protein 2 (MeCP2), which is a chromosomal protein that binds to methylated DNA, highlights two key functional domains—a methyl-
CpG-binding domain (MBD) and a NCoR/SMRT co-repressor interaction domain (NID). Shown as red vertical lines below the schematic are the
positions of all RTT-causing missense mutations (RettBASE; http://mecp2.chw.edu.au/). The positions of three particular RTT-causing missense
mutations—R133C, T158M and R306C, reflecting the spectrum of clinical severity—are indicated above the schematic (modified from [6]).
b The approximate clinical severity of patients possessing the specific missense mutations T158M (red), R306C (blue) or R133C (green), based on
independent studies using a variety of clinical severity score systems, for example [3]. c Scores of phenotypic severity of mouse models
containing the T158M (red), R306C (blue) and R133C (green) missense mutations, in comparison with those of wild-type mice (dark gray
solid line) and Mecp2-null mice (pale gray broken line). The asterisks indicate where no animals of that genotype survived beyond the
indicated time-point. The data are adapted from Brown et al. [2] and are reproduced with permission of Oxford University Press
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the methyl-CpG-binding domain (MBD) and the NCoR/
SMRT co-repressor interaction domain (NID) (Fig. 1)
[6]. With a crystal structure of the MBD bound to meth-
ylated DNA available, we can understand the loss of
DNA binding caused by RTT mutations in the MBD
(reviewed in [6]). Likewise, most amino acids in the
NID—which interact with NCoR/SMRT co-repressor
complexes—when mutated cause RTT syndrome, and all
NID mutations tested so far prevent the interaction with
this large multi-component complex. The NCoR/SMRT
complex includes the transcriptional-repression-
associated histone deactylase HDAC3, thus supporting
the hypothesis that MeCP2 recruits this complex to
methylated sites within the genome to downregulate
transcription (reviewed in [6]).
The notion that MeCP2 recruits gene silencing ma-
chinery is well supported by a variety of experimental
data, but it has taken time to link this model convin-
cingly to the effects of MeCP2 loss on transcription
patterns in the brain. Recent studies, however, have
uncovered striking three-way proportionalities be-
tween DNA methylation levels, MeCP2 binding-site
occupancy and transcriptional inhibition [8, 9]. This
progress has depended on new information regardingthe DNA binding-site specificity of MeCP2 showing
that the di-nucleotide methyl-CA (mCA), as well as
the canonical methyl-CG (mCG), both constitute tar-
get sites. In addition, improved mapping of MeCP2
binding in vivo using chromatin immunoprecipitation
has increasingly taken account of the high frequency
of mCG and mCA (~1 per 100 bp) in the neuronal
genome, which rendered conventional peak-finding
approaches problematic. Finally, well-controlled and
highly replicated RNA-sequencing analysis is required
for sensitive transcriptional profiling. What has
emerged from these precision studies is that MeCP2
exerts a restraining effect on transcription. This effect
is global, gene-body-dependent and subtle, but corre-
lates well with DNA methylation density, in particular
affecting a large proportion of brain-specific genes
that are unusually long [8, 9] (reviewed in [6]). Thus,
in contrast to early expectations that MeCP2 would
alter the expression of a few discrete target genes,
new results portray it as a global transcriptional re-
pressor that modulates gene expression programmes
in a DNA-methylation-dependent manner. It remains
unclear, however, how loss of this genome-wide
modulation of gene expression patterns contributes to
the observed RTT pathologies.
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A major contribution of mouse models has been the
proof-of-principle demonstration that RTT is a revers-
ible (i.e. curable) disorder. Restoration of the gene in
Mecp2-deficient animals with advanced Rett-like signs
led to dramatic restoration of normal breathing, mobility
and other features (reviewed in [6]). These results have
given great impetus to the search for a cure. One
approach is to seek small molecules that reverse the
downstream consequences of MeCP2 deficiency,
whereas an alternative is to rectify the genetic cause of
the disorder through gene therapy, protein replacement
or gene correction [1].
As a global regulator that tunes gene expression, and
perhaps reduces transcriptional noise, it is feasible that a
loss of MeCP2 function causes a transcriptional imbal-
ance leading to a ‘sub-optimal’ brain. This underlying
mechanistic heterogeneity has implications for thera-
peutic approaches for RTT. With many genes mildly
misregulated, it might be difficult to identify a single
pathway that is susceptible to small-molecule regulation
that could cure RTT. More positively, it might be pos-
sible to identify drugs to target certain biochemical path-
ways that are crucial for brain function, and thereby
ameliorate a number of aspects of RTT. Pharmacological
readjustment of key pathways could be of therapeutic
value, even if many other processes remain un-corrected
[1]. In support of this argument, a screen for genetic
suppressors of the mouse Rett-like phenotype detected
multiple hits (cited in [6]), indicating that inhibition of
specific pathways can indeed be beneficial. These results
indicate that it is premature to rule out small-molecule-
based therapeutic approaches at this stage.
Two laboratories have shown that delivery of the
Mecp2 gene using an adeno-associated virus (AAV) vec-
tor is efficient enough to rescue some of the phenotypes
of Mecp2-null male and heterozygous female mice
(reviewed in [1]). Initial concerns about inducing MeCP2
overexpression syndrome, especially in female mice that
express a wild-type copy of the gene in approximately
half of their cells, have so far been ameliorated by the
use of endogenous promoters and systemic injection
routes. There is a long way to go, but initial results sug-
gest that gene therapy could be of clinical utility. The
most desirable therapeutic scenario of all would be to
correct the point mutation itself using CRISPR–Cas9 or
related techniques. In vivo gene disruption of the Mecp2
allele in wild-type mice using AAV vectors to deliver
Cas9 and single guide RNA (sgRNA) has been success-
ful, achieving a knockout of MeCP2 in approximately
70% of cells in the hippocampus [10]. This and other
findings raise the possibility that in vivo correction of
MECP2 mutations will one day be feasible. To achieve
targeting specificity, the RTT mutation itself (or single-nucleotide polymorphisms between the two alleles)
could be used to distinguish mutant and wild-type cop-
ies of MECP2, and thus encourage targeting of only the
mutant MECP2 allele. Technical problems remain—most
notably the restricted payload of AAV vectors requires the
simultaneous use of multiple viruses for delivery of the
many, large gene-editing components, which would
reduce the efficiency of such an approach. Despite these
current limitations, gene editing remains a promising
therapeutic option.
Concluding remarks
Pre-clinical research strongly suggests that RTT could be
one of the first curable neurological disorders. The
application of in-depth, genome-wide approaches and
increasingly sophisticated model systems are painting a
clearer picture of the functional role of MeCP2 in neu-
rons, and this new information promises to guide future
therapeutic strategies. At the same time, multiple ther-
apies are currently being developed—for example gene
therapy, reactivation of the inactive X chromosome and
modulation of neurotransmitter signalling pathways. As
to which of these diverse approaches could be of thera-
peutic value, only time will tell.
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